Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Dec 17, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche said this week that Nestle CEO Paul Bulcke, Deutsche Lufthansa's incoming CEO and Chairman of the Executive Board Christoph Franz, and Royal Dutch Shell CEO Peter Voser will be nominated to serve on its board of directors. The company also said that Walter Frey and Wolfgang Ruttenstorfer will not stand for re-election to the board while Bruno Gehrig, Pius Baschera, Lodewijk de Vink, and Andreas Oeri will be proposed for continuing in their positions.

Med BioGene has named Scott Davis to replace David Matthews as CFO. Davis is a partner of Cross Davis & Company, an accounting and management contract services company.

Thermo Fisher Scientific has appointed Nelson Chai to be a company director and to serve on its audit committee. Chai is executive VP and chief administrative officer and head of strategy of CIT Group. He also has served as president of Bank of America's Asia Pacific branch, and he was executive VP and CFO of NYSE Euronext.

Former National Institutes of Health Director Elias Zerhouni will run global R&D at Sanofi-Aventis, replacing Marc Cluzel, who resigned. Since leaving NIH, Zerhouni has worked as a consultant for Sanofi-Aventis and he has served on the boards at Mayo Clinic and the Lasker Foundation.

Harvard University Provost Steven Hyman plans to leave his position at the end of this academic year in order to take a one-year sabbatical at the Broad Institute of Harvard and MIT. Hyman is a neurobiologist and past director of the National Institute of Mental Health.

InGen Biosciences has named Isabelle Buckle the new CEO of the company. She will replace Jean-Pierre Hermet, who will become company chairman. Buckle formerly was business director for Applied Biosystems' global strategic accounts, and she previously spent six years at Ciphergen Biosystems and nine years at Amersham Biosystems.

Nobel Prize winner John Fenn, a professor at Virginia Commonwealth University, died this past week at the age of 93. Fenn won the Nobel Prize for Chemistry in 2002 for his invention of a technique to detect and characterize large biological molecules with high levels of accuracy. He started at work at VCU in 1994 after spending 20 years at Yale University and working for private sector chemical developers and for the US military. In June 2007, VCU established the John Fenn Chair Professorship in Chemistry to recognize his research contributions.

Epigenomics' Co-founder and CFO Oliver Schacht plans to leave the company in March 2011. The company said that it has reached an agreement to hire an "experienced" CFO, whose name the firm will release in January due to confidentiality obligations, to take over the post in April. The company also plans to recruit a new US-based marketing and sales executive to lead its US operations, which are currently run by Schacht.

John Wilson Hawes, supervisor of the Center for Bioinformatics and Functional Genomics at Miami University, died on December 4 at the age of 46. Hawes formerly was director of the Bioechemistry Biotechnology Facility at Indiana University School of Medicine. He was involved in founding the Protein Expression Research Group at the Association of Biomolecular Resource Facilities, according to ABRF.

Dotmatics has appointed Shikha O'Brien to serve as VP of US business development. O'Brien has worked in the Life Science division at Accelrys, and as a scientist has worked for a number of research groups.

HistoRx has appointed Jack Davis to serve on its board of directors. Davis is the former President and CEO of Dianon Systems, which was bought by LabCorp in 2002. He also has served as CEO of Calypte Biomedical and worldwide GM of Abbott Laboratories' Diagnostics Products business.

Nodality has appointed Gregory Critchfield, former president of Myriad Genetics, to a seat on its board of directors. Before he worked at Myriad, Critchfield was Quest Diagnostics' chief medical and science officer and was partly responsible for Quest's spin out from Corning Clinical Laboratories.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.